InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
28 hedge funds and large institutions have $3.04M invested in InVivo Therapeutics Holdings Corp in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 7 closing their positions.
15% less funds holding
Funds holding: 33 → 28 (-5)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
53% less capital invested
Capital invested by funds: $6.42M → $3.04M (-$3.38M)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
IMS Capital Management
Portland,
Oregon
|
+$162K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$92.6K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$46.3K |
| 4 |
Bank of New York Mellon
New York
|
+$23.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$23.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WF
Welch & Forbes
Boston,
Massachusetts
|
-$324K |
| 2 |
Millennium Management
New York
|
-$208K |
| 3 |
Morgan Stanley
New York
|
-$116K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$78K |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$69.4K |
NVIV Hedge Fund Activity: Q4 2017 in Review
28 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q4 2017, worth a combined $3.04M — down 53% from $6.42M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NVIV and 2 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was IMS Capital Management, adding an estimated $162K. The largest seller was Welch & Forbes, cutting an estimated $324K.
- 28 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q4 2017, down from 33 in Q3 2017.
- Funds reported $3.04M of InVivo Therapeutics Holdings Corp stock for Q4 2017, down 53% quarter-over-quarter.
- 2 funds opened new InVivo Therapeutics Holdings Corp positions in Q4 2017 and 7 closed out, a net change of -5 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q4 2017 was IMS Capital Management, an estimated $162K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q4 2017 was Welch & Forbes, an estimated $324K sold.
Based on aggregated 13F filings for Q4 2017.